Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

3600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-09-13

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Every year, new molecular agents enter the market with more and more patients receiving these treatments, especially in the metastatic setting. These molecular agents could correspond to immunotherapy and modulators of signaling pathways. More than 50% of cancer patients will receive radiation therapy during the course of their illness, including radiotherapy aimed a palliating symptoms secondary to metastatic diseases. Therefore, there will be an increasing number of patients who will be receiving radiotherapy while they are still receiving molecular agents. A better understanding of the interaction of these two treatment modalities is needed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Technological Innovation in Radiotherapy

NCT03378856

Cancer Radiotherapy Side Effect

RECRUITING

Involvement of the Immune System in Intrinsic Radiosensitivity

NCT06826066

Neoplasms

RECRUITING NA

The Use of Photobiomodulation in the Management of Radiodermatitis in Head and Neck Cancer Patients

NCT05557825

Radiodermatitis; Acute Radiotherapy Side Effect Head and Neck Cancer

COMPLETED

Radiation Impact on Thromboembolic Events

NCT02696447

Malignant Neoplasm

COMPLETED

Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung Cancer

NCT03406468

Non-Small Cell Carcinoma of Lung, TNM Stage 4

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Every year, new molecular agents enter the market with more and more patients receiving these treatments, especially in the metastatic setting. These molecular agents could correspond to immunotherapy and modulators of signaling pathways. More than 50% of cancer patients will receive radiation therapy during the course of their illness, including radiotherapy aimed a palliating symptoms secondary to metastatic diseases. Therefore, there will be an increasing number of patients who will be receiving radiotherapy while they are still receiving molecular agents. A better understanding of the interaction of these two treatment modalities is needed.

It is within this context that this registry was set up to gather information from physicians and patients treated with molecular agents and radiation therapy. The information being collected include diagnosis, doses received, type of targeted therapy, side effects, etc. Through this registry, we wish to determine whether there are more Grade 3 or above side effects than what is reported in the literature for these treatment modalities, when given alone or in combination. Participating patients will also describe their perceived side effects and quality of life.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Radiotherapy Side Effect

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Combined modality

Patients receiving radiotherapy and a molecular agent for the treatment of cancer

Radiotherapy

Intervention Type RADIATION

Combined modality

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Radiotherapy

Combined modality

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Anti-neoplastic Molecular Agent

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Consent to be part of the AtTRIBut registry
* Prior histological diagnosis of primary cancer.
* If the patient has metastatic disease, there must be radiological or pathological evidence of metastasis
* Age\> 18 years
* Receiving a molecular therapy
* Indicated to receive radiotherapy
* Radiation therapy can be administered using 3D conventional, IMRT or SBRT techniques.